Archived explainer. For the current picture see today's FBRX page.
FORTE BIOSCIENCES IN Equity (FBRX) is drawing unusual attention today. Our newswire has captured 26 stories on FBRX across 16 sources in the last 36 hours, with AI sentiment reading bullish (avg 65/100).
FBRX stock is moving sharply higher today, surging 39.3% in intraday trading after argenx announced a $2.2 billion agreement to acquire Forte Biosciences. The deal values the biotechnology company at $77 per share, a price that represents a significant premium to its recent performance and creates immediate upside for shareholders. The transaction is expected to expand argenx’s immunology pipeline through the inclusion of FB102, a first-in-class anti-CD122 antibody in development for autoimmune diseases.
Forte Biosciences shares opened at $76.32, a 39.3% increase from the previous close of $54.78. The stock traded in a narrow range throughout the session, with a high of $76.72 and a low of $76.30. The deal with argenx, which is valued at approximately $2.2 billion, includes the addition of FB102 to argenx’s portfolio. This acquisition aligns with argenx’s strategic focus on expanding its autoimmune drug offerings and strengthening its position in the immunology space. The transaction has drawn attention from analysts and investors, with some suggesting the deal may cap near-term upside for FBRX shares.
In the last eight trading sessions, FBRX shares have risen 70.0%, from $44.99 to $76.50. The stock has traded between $9.10 and $62.46 over the past 52 weeks. Intraday volume has reached 16.6 million shares, which is 36.0 times the 3-month daily average. Unusual options activity has also been noted, with a notable put premium of $14,000 in the last 36 hours. The stock’s beta of 2.84 highlights its volatility relative to the broader market.
The acquisition is expected to close in the coming months, but no specific timeline has been provided. Investors should monitor the progress of the deal and any regulatory developments that could impact the transaction.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Forte Biosciences stock soars on a $2.2 billion takeover proposal from Argenx. But is there any further upside left in FBRX shares? Let’s find out!
Forte Biosciences is being acquired by Argenx for $2.2 billion [$77/share], capping near-term upside. Click here to read my most recent analysis.
Forte Biosciences (NASDAQ:FBRX) shares surged about 40% to around $76 on Monday after argenx (NASDAQ:ARGX) announced an agreement to acquire the biotechnology company in a deal valued at approximately $2.2 billion. Under the terms of the agreement, argenx will acquire all outstanding Forte...
argenx SE’s $2.2B Forte Biosciences, Inc. deal adds FB-102 to expand pipeline, but valuation & Vyvgart patent risks raise caution. Click for more on ARGX and FRBX.
argenex (NASDAQ:ARGX) said it has agreed to acquire Forte Biosciences in a transaction valued at approximately $2.2 billion in equity value, adding FB102, an anti-CD122 antibody being developed for autoimmune diseases including vitiligo and celiac disease. Under the agreement, argenex will commence
argenx is acquiring Forte Biosciences for $77 per share, marking a significant expansion of its immunology pipeline via the first-in-class anti-CD122 antibody program, FB102. This move underscores argenx's disciplined growth approach, targeting high unmet needs in autoimmune disease treatment.
TD Cowen downgrades Forte Biosciences stock rating on Argenx deal
Shares in Forte Biosciences ($FBRX) were 40% healthier in pre-market trading today after it was bought by peer Argenx ($ARGX) for $2.2 billion. Multiple Autoimmune ...
More on FBRX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier FBRX move explainers: 2026-07-27 · 2026-07-11